---
title: "Health Canada erteilt OraSure Technologies Zulassung für OraQuick HIV-Selbsttest"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275463407.md"
datetime: "2026-02-10T13:05:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275463407.md)
  - [en](https://longbridge.com/en/news/275463407.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275463407.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275463407.md) | [繁體中文](https://longbridge.com/zh-HK/news/275463407.md)


# Health Canada erteilt OraSure Technologies Zulassung für OraQuick HIV-Selbsttest

OraSure Technologies Inc. hat bekannt gegeben, dass der OraQuick HIV Selbsttest eine Zulassung von Health Canada für die Verwendung in Kanada erhalten hat. Der Test ist der erste orale HIV-Selbsttest in Kanada und ermöglicht die Erkennung von Antikörpern gegen HIV-1 und HIV-2 mit einem oralen Abstrich. St. Michael’s Hospital (Unity Health Toronto) übernimmt als exklusiver Distributor die nationale Verteilung des Tests in Kanada. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OraSure Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651301-en) on February 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [OraSure Technologies, Inc. (OSUR.US)](https://longbridge.com/en/quote/OSUR.US.md)

## Related News & Research

- [OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital | OSUR Stock News](https://longbridge.com/en/news/279490096.md)
- [EXCLUSIVE-Altai Capital presses OraSure to sell and give it board seats, letter says](https://longbridge.com/en/news/279426356.md)
- [Gilead Sciences Conference: 6-Month HIV Regimens, 12-Month PrEP, Livdelzi Expansion, Oncology Push](https://longbridge.com/en/news/279409484.md)
- [PayPay CEO Signals Potential Tokyo Listing After US Market Debut](https://longbridge.com/en/news/279176305.md)
- [OraSure Q4 revenue falls 29%, core business down 22%](https://longbridge.com/en/news/276944555.md)